The estrogen-related receptor gamma (ESRRG) gene, also known as ERRγ, locating at the chromosome 1q41 region, is a member of the estrogen-related receptor (ERR) family, an orphan nuclear receptor subgroup.
Therefore, the identification of the molecular mechanisms underlying the development and progression of LSCC is urgently needed for exploring novel therapeutic strategies for LSCC. According to the Global Cancer Statistics, the incidence of laryngeal cancers was much higher in males than in females. 11 Although collected evidence showed a role for epigenetic mechanisms in LSCC, a detailed exploration of the sex difference is lacking.
DNA hypermethylation is a basic epigenetic modification known to be involved in the regulation of gene expression, mRNA splicing, and genomic stability, 12 and it has been intensively and widely studied in cancer epigenetics. 13 Hypermethylation of the tumor suppressor gene (TSG) promoter region is an important mechanism in several types of cancers, such as colorectal cancer 14 and hepatocellular carcinoma. 15 In recent studies, the potential significance of gene methylation for the diagnosis of LSCC has been evaluated. 16, 17 In this study, we assessed the ESRRG promoter methylation status in LSCC by measuring ESRRG promoter methylation in LSCC tissue samples. Moreover, we evaluated the clinical value of the ESRRG promoter methylation status by correlating it to the clinical characteristics and survival of LSCC patients.
| MATERIAL S AND ME THODS

| Patients and tissue samples
A total of 91 pairs of tumor and adjacent nontumor tissue specimens were obtained from LSCC patients at the Department of
Otolaryngology-Head and Neck Surgery at Lihuili Hospital of
Ningbo University in China between 2011 and 2015. All patients were subjected to surgery and diagnosed according to the criteria of the World Health Organization before chemoradiotherapy. All specimens were stored at −80°C immediately after being harvested from fresh tissues during surgery. The adjacent nontumor tissues were dissected at >0.5 cm from the margin of the neoplastic lesion and confirmed histopathologically. 
| DNA extraction and bisulfite modification
Genomic DNA was extracted from tissue samples in accordance with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) instructions. Subsequently, the DNA concentrations and quality were evaluated by a NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific Co. Ltd., Wilmington, DE, USA). All DNA absorbance ratios at 260/280 nm were between 1.8 and 2.0. The extracted DNA was chemically modified with a ZYMO EZ DNA Methylation-Gold Kit (Zymo Research, Orange, CA, USA).
| Pyrosequencing assay
Bisulfate-treated DNA was amplified using polymerase chain reaction (PCR) with a PyroMark PCR Kit (Qiagen) and the forward primer 5′-TAGAGTTAGAGGGAGATGAATTG-3′ and the reverse primer 5′-biotin-TCTTTTCAAATCCATCACTAA-3′. The PCR conditions were as follows: denaturation at 95°C for 10 minutes, 45 cycles at 95°C for 30 seconds, 50°C for 30 seconds, and 72°C for 1 minutes, and final extension at 72°C for 10 minutes. Then, the methylation levels of six CpG sites in the ESRRG promoter were measured via bisulfite pyrosequencing; the sequencing primer used was 5′-GGGAGATGAATTGGG-3′. The pyrosequencing results were confirmed by repeating the tests at least twice.
| Statistical analysis
All statistical analyses were performed by SPSS v22. ing characteristic (ROC) curve analyses were conducted to assess the diagnostic value of ESRRG promoter methylation for LSCC. 18 The area under the ROC curve (AUC) was determined with a 95% CI. The overall survival rate (OSR) of LSCC patients according to the ESRRG methylation status was compared using the Kaplan-Meier survival method and the log-rank test. Statistical significance was considered at a P value of <0.05. All figures were generated using GraphPad Prism 6 software (GraphPad Inc, San Diego, CA, USA).
| RE SULTS
| Hypermethylation of the ESRRG promoter in tumor samples
In our study, bisulfite pyrosequencing was performed to evaluate the ESRRG promoter methylation status in 91 primary LSCC tissues and paired adjacent nontumor tissues. There are three CpG islands in the ESRRG promoter, Chr1: 217307745-217309179, Chr1:
217310750-217311178, and Chr1: 217311468-217311773. We used Pyromark Q96 Pyrosequencing System software to score the sites of these CpG islands (CGIs) on the ESRRG promoter. Six sites selected from a fragment in a CGI of the ESRRG promoter were detected, as shown in Figure 1 . As shown in Table 1 , the methylation levels of each of the six CpG sites were significantly higher in the tumor samples than in the paired samples (CpG1-6: all P < 0.01).
Representative pyrograms are shown in Figure 2A . In addition, all correlation comparisons among the methylation levels of the six CpGs were significant ( Figure 1 , r > 0.8, P < 0.01). Thus, the methylation index (MI) was calculated as the mean percent methylation across the six CpG sites in the ESRRG promoter. 19 The MI was significantly higher for the tumor samples (36.18 ± 14.54%) than for the adjacent nontumor samples (21.11 ± 10.45%; P < 0.01; Figure 2B ).
| Association of ESRRG promoter methylation with clinical characteristics
In addition, we explored the association of ESRRG promoter methylation levels with clinical characteristics, including age, smoking behavior (patients who never smoked were defined as nonsmokers), Table 2 , the ESRRG promoter methylation levels were markedly increased in patients with advanced T stage tumors (P < 0.01) and advanced clinical stage disease (P < 0.01), while no significant correlation was observed between methylation and any other clinical characteristic (P > 0.05).
| Diagnostic value of ESRRG promoter methylation
A ROC curve analysis of ESRRG promoter methylation was performed to evaluate the diagnostic potential of ESRRG methylation levels for LSCC by calculating the AUC for nontumor samples as the control, as shown in Figure 3A . At a diagnostic threshold value (cutoff value) of 26.58% for the ESRRG promoter MI, the AUC, sensitivity, and specificity were 0.81 (95% CI = 0.75-0.88, P < 0.01), 70.33%, and 80.22%, respectively. Artificially, an MI above the cut-off value was defined as a positive diagnostic indicator, while an MI below the cut-off value was defined as a negative indicator. Then, the falsenegative and false-positive rates were 19.78% and 29.67%, respectively. The positive and negative predictive values were 78.05% and 73.00%, respectively. The diagnostic concordance rate was 75.27%.
| Association of ESRRG promoter methylation with LSCC patient prognosis
Kaplan-Meier survival analysis was performed to evaluate the prognostic potential of ESRRG methylation for LSCC patients who survived for 5 years. Based on the previously described ROC curve results, the patients were divided into two groups by using a mean MI of 26.58% for the 91 LSCC patient samples as a cut-off value.
The patients were divided into two groups: a hypermethylation group (n = 63) and a hypomethylation group (n = 28). In addition, we the epithelial-mesenchymal transition (EMT) process. Similarly, hypermethylation of the miR-145-5p promoter inhibits the expression of miR-145-5p which is a negative regulator of fascin actin-bundling protein 1 (FSCN1), this effect is associated with the migration, invasion, and growth of LSCC because EMT is suppressed, and cell-cycle arrest and apoptosis are induced. 22 Promoter methylation of both ZNF667-AS1 and miR-145-5p is an important potential prognostic marker and therapeutic target for LSCC. Targeted therapies for nonsmall cell lung cancer (NSCLC), an incurable disease, have improved the survival of NSCLC patients. 23 In addition to targeted therapies for LSCC, early-stage diagnosis of LSCC is needed. LSCC is an aggressive malignancy, and abundant evidence has shown that most LSCC patients are male. 24 An understanding of the mechanisms underlying the sex difference in LSCC could lead to therapeutic targets, which are urgently needed. ESRRG has been studied extensively in female tumors and has been shown to play a tumor-suppressive role.
| D ISCUSS I ON
However, recent studies reported that ESRRG exerted oncogenic potential in breast cancer by increasing the expression of E-cadherin, which promoted mesenchymal-to-epithelial transition (MET) in vivo. 25 6 In conclusion, ESRRG plays a role in inhibiting tumor growth, metastasis and invasion and could be a potential diagnostic F I G U R E 3 Receiver operating characteristic (ROC) curve and overall survival (OS) analysis stratified by the ESRRG promoter methylation status in patients with laryngeal squamous cell carcinoma (LSCC). A, ROC curve analysis for the ESRRG promoter methylation status in LSCC patients (n = 91). The black arrow indicates the best cut-off point for the ESRRG methylation status, which is 26.58% (AUC = 0.81, 95% CI = 0.75-0.88, P < 0.01, sensitivity = 70.33% and specificity = 80.22%). B-D, The OS time of LSCC patients with ESRRG promoter hypomethylation was longer than that of patients with ESRRG promoter hypermethylation. The Kaplan-Meier survival curves of (B) all LSCC patients (n = 91, P < 0.01), (C) patients with early clinical stage disease (I and II, n = 45, P = 0.04) and (D) patients with advanced clinical stage disease (III and IV, n = 46, P = 0.02) indicated an effect of the ESRRG promoter methylation status on 5-year survival by the log-rank test. A hypomethylation group (MI < 26.58%) and hypermethylation group (MI > 26.58%) were defined. H, hypermethylation group; L, hypomethylation group and prognostic biomarker for these cancers. However, the roles of the ESRRG in LSCC progression are unclear. Therefore, the purpose of the study was to explore whether ESRRG plays a role in inhibiting tumor growth, metastasis, and invasion in LSCC, and whether ESRRG could be a potential diagnostic and prognostic biomarker for LSCC.
As used in the current study, identifying epigenetic modifications in genes is an important approach to understand.
We therefore validated the methylation status of the ESRRG promoter in LSCC tumor samples relative to that in tumor-adjacent normal tissues by pyrosequencing and further analyzed the clinical utility of the ESRRG promoter methylation status. In the present study, six sites were identified in a CGI of the ESRRG promoter in Figure 1 . 
| CON CLUS IONS
In conclusion, the current study showed that the ESRRG promoter was highly methylated in LSCC tumor tissues and that its hypermethylation was significantly associated with advanced T stage tumors and advanced clinical stage patients. In addition, the ESRRG promoter methylation status could be a biomarker to diagnose LSCC and assess prognosis. 
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